🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

6 recruiting trials

for Ph-Like

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL NCT07454226NA1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Olverembatinib, Gecacitinib, Venetoclax, Chemotherapy Regimen, Blinatumomab RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL NCT05127148n/a2 sites📍 Paraná📍 CABA Grupo Argentino de Tratamiento de la Leucemia Aguda · Tests: Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT06124157Phase 2161 sites📍 Birmingham📍 Phoenix📍 Tucson National Cancer Institute (NCI) · Tests: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Inotuzumab Ozogamicin Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia NCT03571321Phase 12 sites📍 Chicago📍 Dallas University of Chicago · Tests: Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) NCT07387926Phase 1, Phase 24 sites📍 Sydney📍 Ramat Gan📍 Seoul Novartis Pharmaceuticals · Tests: Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone, Vincristine, Blinatumomab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy